- Home
- LRE vs TIL Comparison
LRE vs TIL Comparison
Compare LRE & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- TIL
- Stock Information
- Founded
- LRE 2001
- TIL 2018
- Country
- LRE Japan
- TIL United States
- Employees
- LRE N/A
- TIL N/A
- Industry
- LRE
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- TIL Health Care
- Exchange
- LRE Nasdaq
- TIL Nasdaq
- Market Cap
- LRE 17.6M
- TIL 230.1M
- IPO Year
- LRE 2023
- TIL 2021
- Fundamental
- Price
- LRE $1.76
- TIL $24.49
- Analyst Decision
- LRE
- TIL Buy
- Analyst Count
- LRE 0
- TIL 5
- Target Price
- LRE N/A
- TIL $119.00
- AVG Volume (30 Days)
- LRE 11.2K
- TIL 310.3K
- Earning Date
- LRE 01-01-0001
- TIL 08-12-2025
- Dividend Yield
- LRE N/A
- TIL N/A
- EPS Growth
- LRE N/A
- TIL N/A
- EPS
- LRE N/A
- TIL N/A
- Revenue
- LRE $110,330,328.00
- TIL N/A
- Revenue This Year
- LRE N/A
- TIL N/A
- Revenue Next Year
- LRE N/A
- TIL N/A
- P/E Ratio
- LRE N/A
- TIL N/A
- Revenue Growth
- LRE 3.92
- TIL N/A
- 52 Week Low
- LRE $1.10
- TIL $9.70
- 52 Week High
- LRE $2.49
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- LRE 54.52
- TIL 47.69
- Support Level
- LRE $1.71
- TIL $21.80
- Resistance Level
- LRE $1.78
- TIL $26.91
- Average True Range (ATR)
- LRE 0.08
- TIL 3.52
- MACD
- LRE -0.01
- TIL -0.37
- Stochastic Oscillator
- LRE 28.78
- TIL 35.14
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.